[Concurrent radiotherapy combined with carboplatin and etoposide in limited stage small cell lung cancer].
OBJECTIVE
To observe the effect of concurrent radiotherapy combined with carboplatin and etoposide in limited stage small cell lung cancer.


METHODS
Ninety patients with limited stage small cell lung cancer were randomized into two groups, concurrent treatment group (group A) and sequential treatment group (group B). All the patients in two groups received radiotherapy (60 Gy in 6 weeks) and six courses of chemotherapy (carboplatin and etoposide). Radiotherapy was started in the first course of chemotherapy in group A. Patients of group B were treated by radiation between the fourth and the fifth course of chemotherapy.


RESULTS
The median survival time was 26 months in group A and 19 months in group B. The 5-year survival rate was 27% in group A and 16% in group B. The major toxic reactions were grade III-IV myelosuppression. The differences of two groups were significant (P < 0.05).


CONCLUSIONS
Concurrent radiotherapy combined with carboplatin and etoposide can significantly improve median survival time and 5-year survival rate of patients with limited stage small cell lung cancer.
Qiao
Tian-kui
TK
Department of Radiotherapy, Jinshan Hospital, Fudan University, Shanghai 200540, China.
Zhou
Dao-an
DA
Xin
Li
L
Shu
Li
L
Wu
Wei
W
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000532:radiotherapy* / Q000556:secondary; D003131:Combined Modality Therapy / Q000379:methods; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011882:Radiotherapy, High-Energy; D015996:Survival Rate
D005047:Etoposide; D016190:Carboplatin